Lupus

Oral TLR7/8 inhibitor enpatoran earns FDA Breakthrough status for lupus skin disease, with Phase 2 CLASI-A gains and Phase 3 underway.

Richard Furie, MD, discusses phase 2 JASMINE data showing sustained SRI-4 and LLDAS responses through 52 weeks.

The FDA approved anifrolumab via a once-weekly subcutaneous autoinjector for moderate to severe SLE based on phase 3 TULIP-SC trial results.

FDA reviews Gazyva for systemic lupus after ALLEGORY shows stronger responses, fewer flares and steroid use—potential first anti‑CD20 option for SLE.

This rheumatology month in review emphasizes impactful conversations from RWCS 2026 and the launch of the Joint Ventures podcast.

The decision is supported by data from the phase 2b JASMINE study which will be presented at a future medical meeting.

This rheumatology month in review emphasizes new data and FDA actions.

The FDA designates litifilimab as a breakthrough therapy for cutaneous lupus erythematosus, highlighting its potential to transform treatment options.

Subcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.

This rheumatology month in review emphasizes new data and impactful approvals.

The Q4 recap for rheumatology spotlights regulatory and clinical advances across rheumatic diseases.

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

Topline results show GLPG3667 met its primary endpoint in a phase 3-enabling dermatomyositis trial but missed in systemic lupus erythematosus.

A BTK inhibitor, orelabrutib, met its primary endpoint in a phase 2b trial for systemic lupus erythematosus, with further approval for a phase 3 trial evaluation.

This rheumatology month in review emphasizes new data from the ACR Convergence.

Ramsey-Goldman discussed the potential of NAC for treating systemic lupus erythematosus.

The rheumatology month in review emphasizes new data presented at the 2025 ACR Convergence.

Cuda also discussed further research she'd like to do with cognition and SLE.

Cuda discussed the potential of the NIH toolbox to easily assess cognitive effects in clinical trials.

Cuda discussed the link between SLE disease activity and cognitive deficits,

New research at ACR 2025 highlights the link between cognitive impairment and disease activity in SLE.

Phase 2 trial shows ianalumab achieves sustained lupus disease control, supports steroid tapering, and increases time in remission over 1 year.

Phase 3 data show dapirolizumab pegol improved remission and disease stability in lupus; a second trial and patient-reported outcomes are now underway.